• PengFei Cheng, Hao Wu, JunZhe Yang, XiaoYang Song, MengDa Xu, BiXi Li, JunJun Zhang, MingZhe Qin, Cheng Zhou, and Xiang Zhou.
• Department of Anesthesiology, General Hospital of Central Theater Command of PLA, Wuhan, China.
• Virol J. 2021 Feb 10; 18 (1): 33.

PurposeTo investigate the predictive significance of different pneumonia scoring systems in clinical severity and mortality risk of patients with severe novel coronavirus pneumonia.Materials And MethodsA total of 53 cases of severe novel coronavirus pneumonia were confirmed. The APACHE II, MuLBSTA and CURB-65 scores of different treatment methods were calculated, and the predictive power of each score on clinical respiratory support treatment and mortality risk was compared.ResultsThe APACHE II score showed the largest area under ROC curve in both noninvasive and invasive respiratory support treatment assessments, which is significantly different from that of CURB-65. Further, the MuLBSTA score had the largest area under ROC curve in terms of death risk assessment, which is also significantly different from that of CURB-65; however, no difference was noted with the APACHE II score.ConclusionFor patients with COVID, the APACHE II score is an effective predictor of the disease severity and mortality risk. Further, the MuLBSTA score is a good predictor only in terms of mortality risk.

27 keywords...

hide…